Clinical trial
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
NCT00003253 · Oncotech, Industry · Unknown status
Key facts
| NCT number | NCT00003253 |
|---|---|
| Title | Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer |
| Official title | Assessment of the Predictive Value of the Extreme Drug Resistance (EDR) Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer |
| Lead sponsor | Oncotech, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | paclitaxel, antitumor drug screening assay |
| Enrollment | 100 |
| Start date | Jul 1, 1997 |
| First posted | Nov 26, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: